

**The long-awaited service for cats now released following N-NOSE Dogs**  
**Cancer screening using nematodes for your beloved cats,**  
**'N-NOSE Cats' official website now available**

**– Pre-orders available today, special pricing offers for pre-applicants –**

**HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative: Takaaki Hirotsu (Hereinafter referred to as “HIROTSU”)) has successfully developed a cancer screening specifically designated for cats ‘N-NOSE Cats’, using the technology of the “N-NOSE” nematode cancer screening which has been used by more than 500,000 people. Official website available starting today.**

**Pre-orders are available until November 13, those who apply during this period will receive a special discount of 5,000 yen off the regular price.**

The number one cause of death for both cats and dogs are ‘cancer’. However, up until this point, there has not been an easily accessible cancer screening. We as HIROTSU developed this N-NOSE technology-based cancer screening for pets with the strong wish to protect and help the beloved family-members of cat and dog owners.

After 5 years of joint development and research with cooperating institutions, we were able to start the service, ‘N-NOSE Dogs’, by May of 2023. At the same time, we were developing a service for pet cats. However, cats are more difficult than dogs to collect urine. After many interviews with cat lovers, veterinarians, and nurses at veterinary hospitals regarding the collection of cat urine, we were finally able to offer this service for cats.


N-NOSE Cats is affiliated with 52 veterinary hospitals nationwide. In addition to submitting urine collected at home, those who are not comfortable with urine collection may take the test at a hospital. Affiliated hospitals will be announced on the official website as soon as they are ready.

Official Website : <https://lp.n-nose.com/cat/>



'N-NOSE Cats' can test for the risk of mammary, lymphoma, and other types of cancer commonly found in cats<sup>\*3</sup> by simply just submitting urine. In the worst-case event of the screening coming back with a 'High Possibility of Cancer' result, we provide cost-free services such as further treatment advice from a veterinarian.

#### ■ 'N-NOSE Cats' Overview



Pre-order period: October 11, 2023 ~ November 13, 2023 (Mon)

Pre-order website: <https://lp.n-nose.com/cat/>

Pricing: Pre-order special pricing

11,800 yen (with Tax) per periodic screening  
(Choice of once, twice, or three times a year)

One-time trial screening 14,800 yen (with Tax)  
(Orders placed after the pre-order period will be provided with regular pricing)  
16,800 yen (with Tax) per periodic screening  
One-time trial screening 19,800 yen (with Tax)

Screening kit shipping : Expected to ship sequentially starting November 14, 2023

※1 Cause of death (dog) : アニコム家庭どうぶつ白書 2021 犬の死因 10 歳

Cause of death (cat) : Longevity and mortality in cats:A single institution necropsy study of 3108 cases (1989–2019)

※2 Joint research findings :

[Article]

Dec, 2021 「A new detection method for canine and feline cancer using the olfactory system of nematodes」

(Biochemistry and Biophysics Report)

[Conference presentation]

Nov, 2021 「動物における N-NOSE の検討」 (第 42 回動物臨床医学会年次大会)

Dec, 2021 「ペットにおける N-NOSE の検討」 (第 3 回日本生物診断研究会)

Aug, 2022 「Consideration of expanding the use of N-NOSE for pet」 (18th Global Biomarkers and Clinical Research Summit)

Sep, 2022 「線虫がん検査 N-NOSE の動物への利用拡大について」 (第 165 回獣医学会学術集会)

Sep, 2022 「N-NOSE の犬と猫への応用について」 (日本獣医臨床病理学会 2022 年次大会)

Nov, 2022 「線虫の嗅覚を利用した犬と猫のがん検出方法」 (第 40 回日本獣医師会獣医学術学会年次大会 / 第 21 回アジア獣医師会連合大会)

Dec, 2022 「A new early-stage cancer test using *C. elegans* for canine and feline」

(International Conference of Health Evaluation and Promotion 2022)

※3 Breast cancer, Malignant Lymphoma, Lung adenocarcinoma, Nasal adenocarcinoma

## ■ About HIROTSU Bio Science

We as HIROTSU aim to protect the health and future security of people through research, development, and practical application of unique technology that utilize the capabilities of living organisms. Established in 2016, N-NOSE was put to practical use thanks to our researchers' abundance of ideas and tireless efforts. Despite the importance of extending healthy life expectancy being emphasized, it is said that one in every two people will be diagnosed with cancer in this age of 100-year life expectancy. We strive to contribute to solving these social issues with our groundbreaking "bio-diagnoses" technology that utilized that power of nematodes. These nematodes have an excellent sense of smell and are no match to artificial devices.

Furthermore, in June of 2023, we as HIROTSU signed a memorandum of understanding with the Global Health Equity Fund, an impact fund established in partnership with the WHO Foundation, and also the venture capital firm 'Our Crowd' who strives to support the creation of impact to solve global health problem, regarding the overseas expansion of N-NOSE to countries with inadequate healthcare systems. For the healthy future of many people, we are striving for research, development, and practical application to make bio-diagnosis more accessible and progressive.

Company Name: HIROTSU Bio Science Inc.

Headquarters: New Otani Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo

Name of Representative: Takaaki Hirotsu, CEO

Date of Establishment: August 2016

Main Service: Research, development, and marketing of cancer screenings using nematode and nematode olfactory sensors

Corporate website: <https://hbio.jp/>

### **【For Reference】**

#### **■ About 'N-NOSE Dogs'**

Cancer screening for pet dogs using the technology of N-NOSE. In the past, there was no easily accessible cancer screening for dogs who are not able to communicate their own symptoms. Until now, there have been no cancer tests that can be easily taken by dogs that are unable to complain of symptoms. This test is a simple method of submitting urine to determine the risk of lymphoma, mammary gland cancer, skin cancer, and other cancers\* commonly found in dogs. Service started in May of 2023. (\* Liver cancer, breast cancer, lymphoma, thyroid cancer, multiple myeloma, sarcoma, bone tumor, urothelial carcinoma, brain tumor)

Official service website : <https://lp.n-nose.com/dog/>

### **Press Inquiries**

HIROTSU Bio Science Public Relations

E-mail : [press@hbio.jp](mailto:press@hbio.jp)